8-K: Sotera Health Reports Modest Revenue Growth for 2024, Provides 2025 Outlook

Sotera Health announces its fourth-quarter and full-year 2024 financial results, showing a 4.9% increase in net revenues for the year and provides its initial 2025 outlook.

Summary

• Sotera Health reported a 4.9% increase in net revenues for 2024, reaching $1.10 billion compared to $1.05 billion in 2023.
• Net income for 2024 was $44 million, or $0.16 per diluted share, down from $51 million, or $0.18 per diluted share, in 2023.
• Adjusted EBITDA increased by 3.9% to $549 million in 2024.
• For the fourth quarter of 2024, net revenues decreased by 6.5% to $290 million.
• The company's full-year 2025 outlook projects net revenue growth of 4.0% to 6.0% on a constant currency basis and Adjusted EBITDA growth of 4.5% to 6.5% on a constant currency basis.
• Capital expenditures for 2025 are expected to be in the range of $190 million to $210 million.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reports revenue growth for the year, there are declines in net income and Q4 revenues. The outlook for 2025 is cautiously optimistic.

Positives

• Sotera Health achieved its 19th consecutive year of annual revenue growth.
• Customer satisfaction scores remained strong, exceeding 80%.
• The company strengthened its balance sheet.
• Sterigenics facility expansion was completed.
• Nelson Labs Embedded Labs and Expert Advisory Services segments experienced strong double-digit year-over-year growth.
• Nordion saw high-single digit growth compared to 2023.
• Chris Simon, CEO of Haemonetics, joined the board of directors.
• Vince Petrella was appointed lead independent director.

Negatives

• Net income decreased to $44 million in 2024 from $51 million in 2023.
• Adjusted EPS decreased by $0.02 per diluted share to $0.70 in 2024.
• Fourth-quarter net revenues decreased by 6.5% to $290 million compared to the same period last year.
• Nordion's fourth-quarter net revenues decreased by 28.9% due to the timing of cobalt harvest schedules.
• Nelson Labs' fourth-quarter net revenues decreased by 7.3% due to a decline in Expert Advisory Services revenue.

Risks

• Disruptions in the supply of EO and Cobalt-60 could impact operations.
• Fluctuations in foreign currency exchange rates pose a risk.
• Evolving environmental, health, and safety regulations could increase costs.
• Legal proceedings related to EO emissions could result in liabilities.
• Cybersecurity incidents and data breaches could disrupt operations.
• The company's significant leverage could limit its ability to raise additional capital.

Future Outlook

Sotera Health anticipates net revenue growth of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5% for full-year 2025, both on a constant currency basis.

Management Comments

• Chairman and CEO Michael B. Petras, Jr. stated that the company achieved another year of topand bottom-line growth in 2024, marking the 19th consecutive year of annual revenue growth.
• Petras highlighted milestones including strong customer satisfaction scores, a strengthened balance sheet, Sterigenics facility expansion, and growth in Nelson Labs and Nordion segments.

Industry Context

Sotera Health operates in the healthcare industry, providing sterilization solutions, lab testing, and advisory services, and its performance is influenced by factors such as regulatory changes, supply chain dynamics, and competition.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing the specific growth rates and financial metrics of Sotera Health's direct competitors.
• However, companies like Steris, Advanced Sterilization Products (ASP), and smaller testing labs are in similar markets.
• Steris has shown consistent growth in its healthcare segment, while ASP focuses on infection prevention technologies.
• Sotera Health's Adjusted EBITDA margin of approximately 50% is a key metric to compare against these peers.

Management Changes

Legal Proceedings

• The company faces litigation related to the use, emissions, and releases of EO from its facilities in California, Georgia, Illinois, and New Mexico.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance and future outlook.
• Employees are affected by the company's growth and operational decisions.
• Customers rely on Sotera Health's services to ensure the safety and sterilization of healthcare products.
• Suppliers are impacted by the company's supply chain and material requirements.

Next Steps

• Sotera Health management will host a conference call and webcast to discuss the company's operating highlights and financial results.
• The company will participate in the Barclays 2025 Global Healthcare Conference and the KeyBanc Life Sciences & Medtech Investor Forum.

Key Dates